Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET
Company Participants
Mary Jenkins - Associate Director, Investor Relations & Corporate Communications
Doug Ingram - President & Chief Executive Officer
Dallan Murray - Executive Vice President & Chief Customer Officer
Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer & Head of Research & Development
Ian Estepan - Executive Vice President & Chief Financial Officer
Conference Call Participants
Tazeen Ahmad - Bank of America Securities
Anupam Rama - JMP
Gena Wang - Barclays
Brian Abrahams - RBC Capital
Salveen Richter - Goldman Sachs
Ritu Baral - TD Cowen
Mike Ulz - Morgan Stanley
Brian Skorney - Baird
Uy Ear - Mizuho
Robert Finke - Guggenheim
David Hoang - Citigroup
Kristen Kluska - Cantor Fitzgerald
Biren Amin - Piper Sandler
Gavin Clark-Gartner - Evercore
Gil Blum - Needham & Company
Operator
Good afternoon and thank you for standing by. Welcome to the Sarepta Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your speaker for today, Mary Jenkins, Associate Director, Investor Relations and Corporate Communications. Please go ahead.
Mary Jenkins
Thank you, Lisa, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the second quarter 2024. The press release is available on our website at sarepta.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon. Joining us on the call today are Doug Ingram; Ian Estepan; Dallan Murray; and Dr. Louise Rodino-Klapac. After our formal remarks, we'll open the call for Q&A.
I'd like to note that, during this call, we will be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statements. These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control.
Actual results could materially differ from these forward-looking statements, and any such risks can materially and adversely affect the business, the results of operations, and trading prices for Sarepta's common stock. For a detailed description of applicable risks and uncertainties, we encourage you to review the company's most recent annual quarterly report on Form 10-Q filed with the SEC, as well as the company's other SEC filings.